Pharmacology of Antiviral Drugs

Introduction/Overview

The development and clinical application of antiviral drugs represent a cornerstone of modern therapeutics, fundamentally altering the management of viral infections that were once considered untreatable. Unlike antibacterial agents, antivirals target unique components of the viral life cycle without significantly affecting host cellular processes, presenting distinct pharmacological challenges. The clinical relevance of these agents has been profoundly underscored by global pandemics, highlighting their critical role in reducing morbidity, mortality, and transmission of viral diseases. The field continues to evolve rapidly with the advent of novel mechanisms, combination therapies, and agents targeting emerging viruses.

Learning Objectives

• Classify major antiviral drugs based on their target virus and specific mechanism of action within the viral replication cycle.
• Explain the molecular pharmacodynamics of key antiviral drug classes, including nucleotide/nucleoside analogues, protease inhibitors, and entry inhibitors.
• Analyze the pharmacokinetic profiles of representative antivirals, including considerations for absorption, distribution, metabolism, and excretion.
• Evaluate the approved therapeutic applications, major adverse effect profiles, and significant drug interactions for each major class of antiviral agents.
• Apply knowledge of antiviral pharmacology to special clinical populations, including those with renal or hepatic impairment, pregnant individuals, and pediatric or geriatric patients.

Classification

Antiviral drugs are systematically classified according to the virus they target and their specific point of intervention in the viral replicative cycle. This organizational framework aids in understanding therapeutic strategies and potential cross-resistance patterns.

Classification by Target Virus

• Anti-Herpesvirus Agents: Acyclovir, valacyclovir, famciclovir, ganciclovir, valganciclovir, cidofovir, foscarnet.
• Anti-Influenza Agents: Oseltamivir, zanamivir, peramivir, baloxavir marboxil.
• Anti-Hepatitis Agents:
  • Hepatitis B: Entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, lamivudine.
  • Hepatitis C: Direct-acting antivirals (DAAs) including NS3/4A protease inhibitors (glecaprevir), NS5A inhibitors (velpatasvir), and NS5B polymerase inhibitors (sofosbuvir).
• Anti-Human Immunodeficiency Virus (HIV) Agents: Further subdivided into multiple classes based on mechanism.
• Anti-Cytomegalovirus (CMV) Agents: Ganciclovir, valganciclovir, foscarnet, cidofovir.
• Broad-Spectrum and Emerging Antivirals: Ribavirin, remdesivir, molnupiravir, nirmatrelvir/ritonavir.

Classification by Mechanism of Action

1. Entry/Attachment Inhibitors: Block viral binding or fusion with the host cell membrane (e.g., maraviroc, enfuvirtide).
2. Uncoating Inhibitors: Prevent release of viral genetic material into the host cell (e.g., amantadine, rimantadine – now rarely used due to resistance).
3. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs/NtRTIs): Chain-terminating analogues that inhibit reverse transcription (e.g., zidovudine, tenofovir, lamivudine).
4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Allosteric inhibitors of reverse transcriptase (e.g., efavirenz, rilpivirine).
5. Integrase Strand Transfer Inhibitors (INSTIs): Block integration of viral DNA into the host genome (e.g., raltegravir, dolutegravir, bictegravir).
6. Protease Inhibitors (PIs): Inhibit viral protease, preventing maturation of viral proteins (e.g., lopinavir, darunavir).
7. Polymerase Inhibitors: Inhibit RNA/DNA polymerase activity (e.g., acyclovir, sofosbuvir, remdesivir).
8. Neuraminidase Inhibitors: Inhibit viral release from infected cells (e.g., oseltamivir, zanamivir).
9. Cap-dependent Endonuclease Inhibitors: Inhibit viral mRNA synthesis (e.g., baloxavir marboxil).

Mechanism of Action

The pharmacodynamic action of antiviral drugs is predicated on selective interference with specific, often virus-specific, steps in the replication cycle. This selectivity is crucial for minimizing host toxicity.

Inhibition of Viral Entry

This class prevents the initial establishment of infection. Maraviroc acts as a CCR5 chemokine receptor antagonist, blocking the interaction between the HIV envelope glycoprotein gp120 and the host CCR5 co-receptor, thereby preventing viral entry. Enfuvirtide, a synthetic peptide, binds to gp41 and inhibits the conformational change required for fusion of the viral and host cell membranes. Recent agents for other viruses also target host receptors or viral spike proteins to prevent cellular attachment.

Inhibition of Viral Nucleic Acid Synthesis

This is the most common mechanism among antivirals, primarily involving nucleoside/nucleotide analogues. These prodrugs require intracellular activation by viral or host kinases to their triphosphate forms. The active triphosphate analogues compete with natural nucleotides for incorporation into the elongating viral DNA or RNA chain by viral polymerase. Upon incorporation, they act as chain terminators because they lack the 3′-hydroxyl group necessary for forming the phosphodiester bond with the next incoming nucleotide. Acyclovir, for example, is selectively phosphorylated by herpesvirus thymidine kinase, leading to high concentrations of the active form only in infected cells, which confers its excellent therapeutic index. Ganciclovir, while similar, is activated by a broader range of kinases, contributing to its greater toxicity.

Inhibition of Viral Enzymes: Protease and Integrase

HIV protease inhibitors (PIs) are substrate analogues that bind competitively to the active site of the viral aspartyl protease enzyme. This enzyme is responsible for cleaving the viral Gag and Gag-Pol polyproteins into functional structural proteins and enzymes. Inhibition results in the production of immature, non-infectious viral particles. Integrase strand transfer inhibitors (INSTIs) chelate the divalent metal ions (Mg²⁺ or Mn²⁺) within the active site of HIV integrase, blocking the strand transfer step that inserts viral DNA into the host chromosome.

Inhibition of Viral Release

Neuraminidase inhibitors such as oseltamivir and zanamivir are transition-state analogues of sialic acid. They competitively inhibit influenza virus neuraminidase, an enzyme that cleaves sialic acid residues from glycoproteins on the surface of infected cells and newly formed virions. This cleavage is essential for the release of progeny virions from the host cell and for preventing their aggregation. Inhibition traps virions on the cell surface, reducing viral spread within the respiratory tract.

Other Molecular Mechanisms

Baloxavir marboxil is a prodrug hydrolyzed to baloxavir acid, which selectively inhibits the cap-dependent endonuclease of influenza polymerase. This enzyme cleaves host mRNA caps to prime viral mRNA synthesis, a process known as “cap-snatching.” Inhibition halts viral gene transcription. Ribavirin exhibits multiple proposed mechanisms, including inhibition of inosine monophosphate dehydrogenase (depleting GTP pools), direct inhibition of viral RNA polymerase, and incorporation into viral RNA causing lethal mutagenesis.

Pharmacokinetics

The pharmacokinetic properties of antiviral drugs vary widely between classes and individual agents, significantly influencing dosing regimens, route of administration, and potential for drug interactions.

Absorption

Oral bioavailability ranges from poor to excellent. Nucleoside analogues like acyclovir have low oral bioavailability (10-20%), prompting the development of prodrugs like valacyclovir (54%) and famciclovir (77%) which are esters hydrolyzed to the active parent compound in the intestine and liver. Most HIV protease inhibitors and NNRTIs have variable absorption that is often enhanced by food, while some, like zanamivir, are not orally bioavailable and must be administered via inhalation. The direct-acting antivirals for hepatitis C generally exhibit high oral bioavailability.

Distribution

Volume of distribution (V_d) is a key parameter. Many nucleoside analogues (e.g., acyclovir, ganciclovir) are hydrophilic with low V_d, approximating total body water, resulting in poor penetration into certain sanctuary sites like the central nervous system (CNS), although therapeutic levels in cerebrospinal fluid (CSF) are often achieved. In contrast, lipophilic agents like the NNRTIs and PIs have large V_d values, indicating extensive tissue distribution. Protein binding is highly variable; acyclovir is 99% bound, which can influence drug interactions and dialysis clearance.

Metabolism

Metabolic pathways are diverse. Many antivirals undergo hepatic metabolism via cytochrome P450 (CYP) enzymes. HIV PIs are primarily metabolized by CYP3A4 and are also potent inhibitors or inducers of this isoform, forming the basis for numerous drug-drug interactions. Nucleoside analogues are typically not metabolized by CYP enzymes but are activated intracellularly by kinases to their active triphosphate forms. They are often eliminated unchanged renally. Tenofovir prodrugs (disoproxil fumarate and alafenamide) are hydrolyzed by esterases to tenofovir, which is then phosphorylated. Sofosbuvir is activated by sequential hydrolysis and phosphorylation in the liver.

Excretion

Renal excretion of unchanged drug is the primary elimination pathway for many nucleoside analogues (acyclovir, ganciclovir, cidofovir) and tenofovir. Dosing must be adjusted for renal impairment. Agents with significant hepatic metabolism and biliary excretion (e.g., most HIV PIs, NNRTIs, and hepatitis C DAAs) require caution in hepatic impairment. Elimination half-lives (t_1/2) dictate dosing frequency: lamivudine has a short t_1/2 (~5-7 hours), while the active moiety of bictegravir has a long t_1/2 (> 17 hours), allowing for once-daily dosing.

Therapeutic Uses/Clinical Applications

The clinical application of antiviral drugs spans from episodic treatment of acute infections to long-term suppression of chronic viral diseases and post-exposure prophylaxis.

Herpesvirus Infections

Acyclovir, valacyclovir, and famciclovir are first-line for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Indications include genital herpes (first episode, recurrence, suppression), herpes labialis, herpes zoster (shingles), and chickenpox. Intravenous acyclovir is critical for treating HSV encephalitis and disseminated VZV. Ganciclovir and valganciclovir are first-line for the treatment and prevention of CMV disease in immunocompromised patients, such as transplant recipients and those with advanced HIV.

Human Immunodeficiency Virus (HIV) Infection

Antiretroviral therapy (ART) involves combinations of drugs from at least two different classes to achieve maximal viral suppression and prevent resistance. Standard regimens often consist of two NRTIs plus a third agent from the INSTI, NNRTI, or PI class. Treatment is recommended for all individuals with HIV, regardless of CD4 count, to improve health outcomes and reduce transmission. Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine or tenofovir alafenamide/emtricitabine is highly effective in preventing HIV acquisition in at-risk individuals.

Hepatitis Virus Infections

For chronic hepatitis B, nucleos(t)ide analogues like entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide are used as first-line agents to suppress viral replication, normalize liver enzymes, and reduce the risk of cirrhosis and hepatocellular carcinoma. Treatment is often long-term. For hepatitis C, interferon-free regimens of direct-acting antivirals (DAAs) for 8-12 weeks achieve sustained virologic response (SVR, equivalent to cure) rates exceeding 95% across all genotypes. Regimens are tailored based on viral genotype, prior treatment history, and presence of cirrhosis.

Influenza

Neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) are used for the treatment of acute uncomplicated influenza within 48 hours of symptom onset, though treatment may still be beneficial in hospitalized patients when started later. They are also used for post-exposure prophylaxis in certain settings. Baloxavir marboxil is approved for treatment of acute influenza and has a different mechanism. The utility of these agents can vary with circulating strains and resistance patterns.

Other and Emerging Uses

Ribavirin is used in combination with pegylated interferon for chronic hepatitis C (now largely superseded by DAAs) and as an aerosol for severe respiratory syncytial virus (RSV) infection in hospitalized infants. Remdesivir, a broad-spectrum nucleotide analogue, is approved for the treatment of COVID-19 in hospitalized and non-hospitalized patients. Nirmatrelvir (a SARS-CoV-2 protease inhibitor) co-packaged with ritonavir (a pharmacokinetic enhancer) is authorized for the early outpatient treatment of mild-to-moderate COVID-19 in high-risk individuals.

Adverse Effects

The adverse effect profiles of antiviral drugs are closely linked to their mechanisms, with toxicity often arising from off-target effects on host cellular processes or from the accumulation of metabolites.

Class-Specific Adverse Effects

Nucleoside/Nucleotide Analogues: A common class effect is mitochondrial toxicity, manifesting as lactic acidosis with hepatic steatosis, myopathy, neuropathy, and pancreatitis. This is thought to result from inhibition of mitochondrial DNA polymerase-γ. Zidovudine is associated with bone marrow suppression (anemia, neutropenia) and myopathy. Tenofovir disoproxil fumarate is linked to renal tubular dysfunction (Fanconi syndrome) and reduced bone mineral density, risks that are lower with tenofovir alafenamide.

HIV Protease Inhibitors: Metabolic disturbances are hallmark adverse effects, including insulin resistance and new-onset or exacerbation of diabetes mellitus, hyperlipidemia (elevated triglycerides and cholesterol), and lipodystrophy (peripheral fat loss and central fat accumulation). Gastrointestinal intolerance (nausea, diarrhea) is also common.

Non-Nucleoside Reverse Transcriptase Inhibitors: Effects are agent-specific. Efavirenz is associated with central nervous system effects (dizziness, vivid dreams, insomnia), rash, and potential teratogenicity. Nevirapine carries a risk of severe hepatotoxicity and life-threatening skin reactions, including Stevens-Johnson syndrome.

Anti-Herpesvirus Agents: Acyclovir and valacyclovir are generally well-tolerated but can cause nausea, headache, and, rarely, neurotoxicity (confusion, hallucinations) especially with intravenous dosing in renal impairment. Ganciclovir/valganciclovir cause significant bone marrow suppression (neutropenia, thrombocytopenia) and require regular monitoring.

Serious and Rare Adverse Reactions

• Hypersensitivity Reactions: Abacavir is associated with a potentially fatal hypersensitivity reaction strongly linked to the HLA-B*5701 allele; genetic screening is mandatory prior to initiation.
• Hepatotoxicity: A risk with several agents, including nevirapine, high-dose ritonavir, and some hepatitis C DAAs.
• Renal Toxicity: Cidofovir and intravenous foscarnet can cause severe nephrotoxicity; pre-hydration and probenecid are used with cidofovir to mitigate this risk. Tenofovir disoproxil fumarate can cause renal impairment.
• Black Box Warnings: Several antivirals carry black box warnings, the strongest FDA advisory. Examples include lactic acidosis/hepatic steatosis with NRTIs, severe hepatotoxicity and skin reactions with nevirapine, and the risk of exacerbation of hepatitis B upon discontinuation of certain hepatitis C or HIV therapies.

Drug Interactions

Drug-drug interactions are a major clinical consideration in antiviral therapy, particularly for agents used in chronic management like HIV and HCV drugs. Interactions can be pharmacokinetic (affecting absorption, metabolism, or excretion) or pharmacodynamic.

Major Pharmacokinetic Interactions

Interactions involving hepatic cytochrome P450 enzymes, especially CYP3A4, are pervasive. HIV protease inhibitors and cobicistat (a pharmacokinetic enhancer) are potent inhibitors of CYP3A4. They can significantly increase plasma concentrations of co-administered drugs metabolized by this pathway, such as certain statins (simvastatin, lovastatin), sedative-hypnotics (midazolam, triazolam), and ergot alkaloids, potentially leading to toxicity. Conversely, efavirenz and nevirapine are inducers of CYP3A4 and can reduce concentrations of other drugs, including other antiretrovirals, oral contraceptives, and warfarin, potentially leading to therapeutic failure.

P-glycoprotein and other drug transporters also mediate interactions. Tenofovir absorption is increased by drugs that inhibit P-glycoprotein in the gut. Renal interactions occur with drugs that compete for active tubular secretion; probenecid, for instance, reduces the renal clearance of acyclovir and cidofovir, an effect used therapeutically to protect renal function with cidofovir.

Contraindications and Significant Interactions

• Absolute Contraindications: Use of abacavir in patients positive for HLA-B*5701. Use of simvastatin or lovastatin with strong CYP3A4 inhibitors like protease inhibitors or cobicistat due to high risk of rhabdomyolysis.
• Major Contraindicated Combinations: Concurrent use of two NRTIs that are both potent mitochondrial toxins (e.g., stavudine + didanosine) due to excessive risk of lactic acidosis and pancreatitis. Use of ribavirin with didanosine due to increased risk of mitochondrial toxicity and hepatic failure.
• Narrow Therapeutic Index Drugs: Anticoagulants (warfarin), antiarrhythmics (digoxin, amiodarone), and anticonvulsants (phenytoin, carbamazepine) require close monitoring when co-administered with antivirals that affect CYP enzymes or transporters, as their plasma levels can be significantly altered.

Special Considerations

The use of antiviral drugs requires careful adjustment and monitoring in specific patient populations due to altered pharmacokinetics, increased susceptibility to toxicity, or potential fetal risk.

Pregnancy and Lactation

Treatment of viral infections in pregnancy balances maternal health benefits against potential fetal risks. Several antivirals are used. Acyclovir and valacyclovir are considered safe for treating HSV in pregnancy, including for suppression near term to prevent neonatal herpes. For HIV, combination ART is recommended for all pregnant individuals to prevent mother-to-child transmission; preferred regimens include dual NRTI backbones (tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivudine) combined with a third agent like raltegravir or atazanavir/ritonavir. Efavirenz, once contraindicated, is now considered an alternative. Ribavirin is absolutely contraindicated due to teratogenic and embryocidal effects. Data on newer agents like hepatitis C DAAs and COVID-19 antivirals in pregnancy are limited, and use is generally deferred unless benefits outweigh risks. Many antivirals are excreted in breast milk; decisions regarding breastfeeding must consider the specific drug, maternal health needs, and infant safety.

Pediatric and Geriatric Considerations

Pediatric dosing is typically based on body surface area or weight. Formulation availability (e.g., oral solutions, dispersible tablets) is crucial. Pharmacokinetic parameters such as clearance can differ significantly from adults. For geriatric patients, age-related declines in renal and hepatic function necessitate dose adjustments for renally excreted drugs (acyclovir, ganciclovir, tenofovir) and those metabolized hepatically. Increased prevalence of comorbidities and polypharmacy in this population elevates the risk of drug interactions and adverse effects.

Renal and Hepatic Impairment

Renal Impairment: Dose reduction is essential for drugs primarily excreted unchanged by the kidneys to prevent accumulation and toxicity. This applies to acyclovir, valacyclovir, ganciclovir, cidofovir, foscarnet, and tenofovir disoproxil fumarate. Dosing guidelines often use creatinine clearance (CrCl) thresholds. Some agents, like adefovir, require adjustment even with mild impairment.

Hepatic Impairment: Drugs with extensive hepatic metabolism or a risk of hepatotoxicity require caution. Dose adjustments may be needed for certain HIV PIs and NNRTIs in moderate to severe impairment. Many hepatitis C DAAs have specific usage guidelines or contraindications in patients with moderate to severe hepatic impairment (Child-Pugh B or C), particularly those containing protease inhibitors due to risk of further hepatic decompensation.

Summary/Key Points

• Antiviral drugs are classified by target virus and mechanism of action, with major classes including nucleos(t)ide analogues, protease inhibitors, integrase inhibitors, and neuraminidase inhibitors.
• The mechanism of action is highly specific, targeting viral entry, nucleic acid synthesis, or viral enzyme function, which underpins both efficacy and selectivity.
• Pharmacokinetic properties vary widely; many nucleoside analogues are renally excreted and require dose adjustment in renal impairment, while many HIV drugs are hepatically metabolized, leading to complex drug interactions via CYP450 enzymes.
• Therapeutic applications range from episodic treatment of herpes zoster to lifelong suppression of HIV and curative regimens for hepatitis C, fundamentally altering disease outcomes.
• Adverse effect profiles are class-specific, with notable risks including mitochondrial toxicity (NRTIs), metabolic disturbances (PIs), hematologic toxicity (ganciclovir), and severe hypersensitivity (abacavir).
• Drug interactions, particularly those mediated by CYP3A4 inhibition or induction, are a major clinical management issue, especially in antiretroviral therapy.
• Special population considerations are paramount, requiring dose adjustments in renal/hepatic impairment and careful risk-benefit analysis in pregnancy, pediatrics, and geriatrics.

Clinical Pearls

1. Valacyclovir and famciclovir are prodrugs with significantly improved oral bioavailability compared to acyclovir, allowing for less frequent dosing.
2. The potential for exacerbation of hepatitis B is a critical monitoring point when initiating or discontinuing certain immunosuppressive or antiviral therapies (e.g., rituximab, some HCV DAAs).
3. Genetic screening for HLA-B*5701 is mandatory before initiating abacavir to prevent a potentially fatal hypersensitivity reaction.
4. When treating HIV, combination therapy with agents from at least two different mechanistic classes is essential to suppress viral replication and prevent the emergence of resistance.
5. Renal function must be assessed and monitored regularly during treatment with acyclovir, ganciclovir, cidofovir, foscarnet, or tenofovir disoproxil fumarate, with appropriate dose adjustments.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.